An Khang Brings Medicine Purchase Service to VNeID
On the morning of May 28, the An Khang pharmacy chain signed a contract to deploy electronic authentication services with the Research and Application Center for Population Data and Civil Status (RAR Center) – a unit under the Police Administration Department for Social Order, Ministry of Public Security.
According to the cooperation content, the electronic prescription data of the people will be updated directly on the VNeID application when they go for medical examination and treatment with health insurance. Through this platform, patients can choose to buy medicine at An Khang pharmacy without having to go to the hospital pharmacy. The order can be delivered to the home or picked up at the pharmacy after identity verification via VNeID.

Integrating the pharmacy system into the national identification application is expected to shorten the time to buy medicine, reduce overload at hospital pharmacies, and limit the risk of cross-infection in the medical environment. In addition, people can also look up transaction history and access drug information more conveniently.
In the market, An Khang pharmacy stated that they apply a number of policies to ensure transparency in pharmaceutical retail activities. Specifically, the pharmacy chain commits to no dose cutting fees, especially for drugs treating common diseases such as colds, coughs, and runny noses. At the same time, there are no hidden costs during the sales process. All medicines sold at An Khang are genuine products with clear origins and permitted to circulate. The selling price is listed according to the manufacturer’s price, under strict supervision.
Speaking at the signing ceremony, Mr. Doan Van Hieu Em, CEO of An Khang pharmacy chain, said that health care is not just about helping people treat diseases, but also about transparency in every pill provided.
“For us, health care is not just about helping people get well soon, but also about transparency in every little pill,” he affirmed.
This is An Khang’s Second Golden Opportunity
Also on the morning of May 28, in an interview with the press, Mr. Hieu Em called the present time the “second golden opportunity” for An Khang and the Mobile World Group after the Covid-19 pandemic. According to him, after the restructuring, although the scale of the chain has narrowed down, An Khang has stabilized and is ready to enter a new phase of development.
With the current market context, a series of policies tightening the management of healthcare and health insurance, along with the intensification of the fight against counterfeit and fake drugs, will, according to Mr. Hieu Em, create favorable conditions for the sustainable development of pharmacy chains operating properly. He also said that the pharmaceutical industry in Vietnam has a revenue scale of over $8 billion, a figure that shows that there is still a lot of room for growth, especially when compared to the $10 billion revenue of the phone and appliance industry.

Looking back at An Khang’s development process, Mr. Hieu Em admitted that after being merged by The Gioi Di Dong in 2018, the chain once missed the opportunity to expand because the corporation had to prioritize solving many other problems in the ecosystem. Especially during the pandemic period of 2020-2021, retail chains such as The Gioi Di Dong and Dien May Xanh had to focus on adapting to the difficult context, maintaining operations between the choices of online or offline business, which made An Khang not a priority for investment.
“That was once a great opportunity for An Khang, but we were not really focused at that time. After the pandemic, the economy also fell into a recession, so investing in An Khang was not a priority,” shared Mr. Hieu Em.
However, at present, with a more focused strategy and a favorable market context, An Khang is being reinvested to accelerate again. The CEO of the pharmacy chain believes that this is a particularly important time not only for the pharmaceutical industry but also for many other consumer industries such as food, catering services, and fields directly related to the health and lives of the people.
“SK Group Sells Imexpharm Shares to Chinese Firm at an Average Price of VND 57,400 per Share, Following Suit of Vingroup and Masan.”
With a transaction value of nearly VND 5,731 billion, this deal surpasses the market value by approximately 13% based on the closing price on May 22nd.
The Ultimate Recession-Proof Industry: A $70 Billion Behemoth, with Retail Giants Scrambling to Open Stores in Rural and Urban Areas Alike
The pharmaceutical retail market is often deemed “recession-proof”, owing to the consistent demand for pharmaceuticals, which remains imperative despite macroeconomic fluctuations. In the context of Vietnam, with its aging population and growing middle class, the demand for healthcare, and by extension, the pharmaceutical industry, is experiencing unwavering growth, as highlighted by Vietdata, a prominent provider of reports on the Vietnamese economy.
“DHG Pharma: 5 Decades of Pride, Gratitude and Aspiration”
On August 31st, DHG Pharma, a leading pharmaceutical company in Can Tho, organized its annual traditional walk alongside a celebration of its 50th anniversary. The theme, “50 Years of Unceasing Aspirations,” commemorated the proud journey of DHG Pharma’s generations through the decades.